Novo Nordisk will file semaglutide for MASH next year
pharmaphorum
NOVEMBER 3, 2024
ESSENCE trial of Novo Nordisk's GLP-1 drug semaglutide shows efficacy in MASH, setting up filings in the US and Europe next year
Sun.Nov 03, 2024
115 
When Dysuria Is More Than Just a Urinary Tract Infection
JAMA Internal Medicine
NOVEMBER 3, 2024
This Teachable Moment describes a 66-year-old woman with mild dysuria, vulvar discomfort, and recurrent urinary tract infections.
As Jurisprudence Under Loper Bright Develops, Early Scorecard is Mixed
FDA Law Blog
NOVEMBER 3, 2024
By John W.M. Claud & Sara W. Koblitz & JP Ellison — Back in July, the United States Supreme Court turned the world of administrative law on its head, adding new layers of judicial oversight to what might have previously been thought of as fairly non-descript Federal agency functions. One of those cases was Loper Bright v. Raimondo , which formally overruled the 40-year precedent under Chevron , under which courts gave agencies deference when interpreting statutory ambiguity.
Let's personalize your content